{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:10:15Z","timestamp":1778620215363,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.yebeh.2025.110512","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T15:03:56Z","timestamp":1748703836000},"page":"110512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Levetiracetam for myoclonic seizures in idiopathic generalized epilepsy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"171","author":[{"given":"Alisson Rafael de Oliveira","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor Andrade","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Abreu","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Ferreira de","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2025.110512_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/epi.18435","article-title":"Updated classification of epileptic seizures: position paper of the International League Against Epilepsy","author":"Beniczky","year":"2025","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110512_b0010","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208076","article-title":"Idiopathic generalized epilepsy: misunderstandings, challenges, and opportunities","volume":"102","author":"Devinsky","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40272-019-00325-x","article-title":"A practical guide to treatment of childhood absence epilepsy","volume":"21","author":"Kessler","year":"2019","journal-title":"Paediatr Drugs"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110512_b0030","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1528-1167.2005.04105.x","article-title":"Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy","volume":"46","author":"Khani","year":"2005","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110512_b0035","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.yebeh.2025.110512_b0040","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110512_b0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/epi.17236","article-title":"Ilae definition of the idiopathic generalized epilepsy syndromes: position statement by the ilae task force on nosology and definitions","volume":"63","author":"Hirsch","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110512_b0050","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211037430","article-title":"Efficacy and tolerability of antiseizure drugs","volume":"14","author":"Hakami","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110512_b0055","first-page":"729","article-title":"Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy","volume":"3","author":"Auvin","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110512_b0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/WNL.0b013e31827f0874","article-title":"Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers","volume":"80","author":"Mawhinney","year":"2013","journal-title":"Neurology"},{"issue":"9566","key":"10.1016\/j.yebeh.2025.110512_b0060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2025.110512_b0065","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.yebeh.2016.07.011","article-title":"Electroclinical aspects and therapy of Han patients with juvenile myoclonic epilepsy in northern China","volume":"62","author":"Wang","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"10282","key":"10.1016\/j.yebeh.2025.110512_b0190","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2025.110512_b0285","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2025.110512_b0290","unstructured":"Reeves BC, Deeks JJ, Higgins JPT, Shea B, Tugwell P, Wells GA. Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023."},{"key":"10.1016\/j.yebeh.2025.110512_b0075","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Sterne JAC, Savovi\u0107 J, Page MJ, Hr\u00f3bjartsson A, Boutron I, et al. A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane Methods. Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1). https:\/\/doi.org\/10.1002\/14651858.CD201601.","DOI":"10.1002\/14651858.CD201601"},{"key":"10.1016\/j.yebeh.2025.110512_b0080","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"159","key":"10.1016\/j.yebeh.2025.110512_b0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2023.05.010","article-title":"The development methods of official GRADE articles and requirements for claiming the use of GRADE - a statement by the GRADE Guidance Group","volume":"19","author":"Schunemann","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110512_b0255","first-page":"617","article-title":"Efficacy of levetiracetam, lamotrigine and sodium valproate on seizure attacks and EEG disorders in patients with juvenile myoclonic epilepsy: a double blind randomized clinical trial","volume":"13","author":"Daneshyar","year":"2022","journal-title":"Caspian J Intern Med"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110512_b0270","article-title":"Comparison of levetiracetam with sodium valproate in controlling seizure in patients suffering from juvenile myoclonic epilepsy. Jentashapir","volume":"5","author":"Kashipazha","year":"2014","journal-title":"J Cell Mol Biol"},{"key":"10.1016\/j.yebeh.2025.110512_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106214","article-title":"Levetiracetam in genetic generalized epilepsy: a prospective unblinded active-controlled trial","volume":"157","author":"Tabrizi","year":"2019","journal-title":"Epilepsy Res"},{"issue":"16_supplement","key":"10.1016\/j.yebeh.2025.110512_b0250","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.86.16_supplement.P2.059","article-title":"Levetiracetam monotherapy is as effective as valproate in newly diagnosed cases with juvenile myoclonic epilepsy (Jme) (P2.059)","volume":"86","author":"Alhamrani","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110512_b0215","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ane.13556","article-title":"Seizure outcome trajectories in a well-defined cohort of newly diagnosed juvenile myoclonic epilepsy patients","volume":"145","author":"Cerulli Irelli","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"10.1016\/j.yebeh.2025.110512_b0210","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaneurol.2023.3400","article-title":"Levetiracetam vs lamotrigine as first-line antiseizure medication in female patients with idiopathic generalized epilepsy","volume":"80","author":"Cerulli Irelli","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2025.110512_b0225","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eplepsyres.2015.11.012","article-title":"Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate","volume":"119","author":"Chowdhury","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110512_b0260","unstructured":"Gamirova R, Shaimardanova R, Gorobets E. The effectiveness of monotherapy in juvenile myoclonic epilepsy. In: Vol 28. European Journal of Neurology; 2021:604. https:\/\/www.ean.org\/fileadmin\/user_upload\/ean\/congress-2021\/EAN2021AbstractBook.pdf."},{"issue":"4","key":"10.1016\/j.yebeh.2025.110512_b0275","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ane.13567","article-title":"Treatment outcomes in women with idiopathic generalized epilepsy","volume":"145","author":"Kiiski","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2025.110512_b0230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yebeh.2019.05.021","article-title":"Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy","volume":"98","author":"Johannessen Landmark","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110512_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107706","article-title":"Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: a single center retrospective study","volume":"115","author":"Milano","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110512_b0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/WNF.0000000000000177","article-title":"Levetiracetam and valproate retention rate in juvenile myoclonic epilepsy","volume":"39","author":"Sala-Padr\u00f3","year":"2016","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110512_b0220","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110512_b0105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/epi4.12321","article-title":"Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients","volume":"4","author":"Zhang","year":"2019","journal-title":"Epilepsia Open"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1535-7511.2008.01274.x","article-title":"Juvenile myoclonic epilepsy: more trials are needed to guide therapy","volume":"9","author":"Abou-Khalil","year":"2009","journal-title":"Epilepsy Curr"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-8749.2007.02009.x","article-title":"Levetiracetam in juvenile myoclonic epilepsy: long\u2010term efficacy in newly diagnosed adolescents","volume":"50","author":"Verrotti","year":"2008","journal-title":"Develop Med Child Neuro"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.seizure.2007.07.001","article-title":"Levetiracetam monotherapy in juvenile myoclonic epilepsy","volume":"17","author":"Sharpe","year":"2008","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110512_b0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1090-3798(03)00041-2","article-title":"Effect of levetiracetam in refractory childhood epilepsy syndromes","volume":"7","author":"Lagae","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110512_b0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.seizure.2003.06.001","article-title":"Levetiracetam as add-on therapy in generalized epilepsies","volume":"13","author":"Kumar","year":"2004","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110512_b0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ane.13389","article-title":"Levetiracetam as first\u2010line monotherapy for Idiopathic Generalized Epilepsy in women","volume":"143","author":"Ballv\u00e9","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1528-1167.2011.03300.x","article-title":"Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open\u2010label, noncomparative, multicenter, long\u2010term follow\u2010up study","volume":"53","author":"Delanty","year":"2012","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110512_b0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1684\/j.1950-6945.2005.tb00127.x","article-title":"Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes","volume":"7","author":"Di Bonaventura","year":"2005","journal-title":"Epileptic Disord"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110512_b0130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1059-1311(03)00139-0","article-title":"Levetiracetam treatment of idiopathic generalised epilepsy","volume":"12","author":"Krauss","year":"2003","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110512_b0135","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.seizure.2005.12.004","article-title":"Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study","volume":"15","author":"Labate","year":"2006","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2004.02.006","article-title":"Levetiracetam in refractory epilepsy: a prospective observational study","volume":"14","author":"Mohanraj","year":"2005","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","article-title":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","volume":"71","author":"Specchio","year":"2006","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(88)90050-2","article-title":"Review of valproate monotherapy in the treatment of generalized tonic-clonic seizures","volume":"84","author":"Wilder","year":"1988","journal-title":"Am J Med"},{"issue":"15","key":"10.1016\/j.yebeh.2025.110512_b0155","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.yebeh.2025.110512_b0160","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"11","author":"Weston","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110512_b0165","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamaneurol.2024.0258","article-title":"Risk of major congenital malformations and exposure to antiseizure medication monotherapy","volume":"81","author":"Battino","year":"2024","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110512_b0170","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/epi.13007","article-title":"Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy","volume":"56","author":"Wood","year":"2015","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2025.110512_b0175","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110512_b0180","first-page":"1","article-title":"Levetiracetam: Pharmacological properties, safety and efficacy in the pediatric population with epilepsy","volume":"12","author":"Ansari","year":"2014","journal-title":"J Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110512_b0185","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1535-7511.2005.00056.x","article-title":"Psychotropic effects of antiepileptic drugs","volume":"5","author":"Nadkarni","year":"2005","journal-title":"Epilepsy Curr"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110512_b0195","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"6","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2025.110512_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106408","article-title":"Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world","volume":"166","author":"Li","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110512_b0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jocn.2022.02.035","article-title":"Rational therapy with lamotrigine or levetiracetam: which one to select?","volume":"99","author":"Asadi-Pooya","year":"2022","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.yebeh.2025.110512_b0235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.seizure.2022.05.005","article-title":"Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: a retrospective multi-center study from Turkey between 2010 and 2020","volume":"99","author":"K\u0131l\u0131\u00e7","year":"2022","journal-title":"Seizure: Eur J Epilepsy"},{"key":"10.1016\/j.yebeh.2025.110512_b0240","doi-asserted-by":"crossref","unstructured":"Pharm J, PJ, November 2023;311(7979). https:\/\/doi.org\/10.1211\/PJ.2023.1.202975.","DOI":"10.1211\/PJ.2023.1.202975"},{"key":"10.1016\/j.yebeh.2025.110512_b0245","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yebeh.2019.05.024","article-title":"Valproate and female patients: prescribing attitudes of Italian epileptologists","volume":"97","author":"Giuliano","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110512_b0305","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0354","article-title":"Second-line medications for women aged 10 to 50 years with idiopathic generalized epilepsy","volume":"8","author":"Cerulli Irelli","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.yebeh.2025.110512_b0310","unstructured":"UCB Biopharma S.A.; 2024. Keppra 500 mg (Levetiracetam). U.S. Food and Drug Administration: Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/021035s115,021505s053lbl.pdf."},{"key":"10.1016\/j.yebeh.2025.110512_b0315","unstructured":"UCB Pharma Limited; 2024. Keppra 500 mg (Levetiracetam). SmPC. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/2293\/smpc."},{"issue":"5","key":"10.1016\/j.yebeh.2025.110512_b0320","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40263-015-0248-9","article-title":"Levetiracetam monotherapy in children with epilepsy: a systematic review","volume":"29","author":"Weijenberg","year":"2015","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110512_b0325","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10309-024-00663-y","article-title":"Erster epileptischer Anfall und Epilepsien im Erwachsenenalter","volume":"37","author":"Holtkamp","year":"2024","journal-title":"Clin Epileptol"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110512_b0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029811","article-title":"Efficacy and safety of levetiracetam in children with epilepsy: protocol for an umbrella review of systematic reviews and meta-analyses of randomised controlled trials","volume":"9","author":"Gan","year":"2019","journal-title":"BMJ Open"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:16:58Z","timestamp":1778617018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505025002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"alternative-id":["S1525505025002525"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110512","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levetiracetam for myoclonic seizures in idiopathic generalized epilepsy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110512"}}